Health & Life Sciences


Susan B. Trujillo quoted in article “3 Takeaways From FDA’s Drug Compounding Guidances”


Below is an excerpt:

Quarles & Brady LLP partner Susan B. Trujillo predicted that the FDA's position will draw fire from 503B outsourcing facilities that invested heavily in manufacturing upgrades but expected to maintain the capacity to operate more flexibly in certain areas as 503A pharmacies.

"I think this is going to have a big impact, especially in places that have already put an outsourcing facility at a location," Trujillo said.


Payment Portal

You are leaving the Quarles & Brady website and being directed to the bill presentment and paying service offered by a third party provider. If you do not wish to continue to the site, click Close or use the Back button on your web browser to return the Quarles & Brady website.